Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
CURED
December 09, 2017
Ash 2017 – An early beta-thalassaemia challenge from Glaxosmithkline
December 07, 2017
Ash therapy focus – the other amyloidosis gets its day in the sun
November 28, 2017
Immuno-oncology combos – what will be hot in 2018?
July 28, 2017
Upcoming events – FDA approvals due for Maviret and Besponsa
July 21, 2017
Snippet roundup: a lingering Lingo and two more US green lights
June 05, 2017
Asco – Mystery Chinese group gives Bluebird a run for its money
February 27, 2017
Merck’s Idenix write-off another bad sign in hep C
February 27, 2017
Merck’s Idenix write-off another bad sign in hep C
November 15, 2016
After the deluge, hep C players look for opportunity
September 07, 2016
How Gilead could go back to basics
July 27, 2016
Gilead lives and dies by hep C
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
March 22, 2021
AACR 2021 preview – the early themes emerge
March 24, 2021
Big pharma’s key catalysts in the second quarter
March 03, 2021
A busy year ahead for Parkinson’s disease
March 23, 2021
Frequency refuses to hear the death knell
February 18, 2021
The reckoning begins for biotech-focused Spacs
